Organic Process Research & Development · 2002 · 111 citations · 7 references
Other Urea TargetsMedicinal ChemistryBioorganic ChemistryScaleable SynthesisMedicineNatural SciencesCancer GrowthScaled QuantitiesAnti-cancer AgentUrea 3Cancer TreatmentDrug DevelopmentBiomolecular EngineeringPharmacologyRadiation OncologyNovel TherapyCancer ResearchDrug Discovery
Urea 3 (BAY 43-9006), a potent Raf kinase inhibitor, was prepared in four steps with an overall yield of 63%. Significant process research enabled isolation of each intermediate and target without chromatographic purification, and overall yield increases >50% were observed compared to those from previous methods. This report focuses on improved synthetic strategies for production of scaled quantities of 3 for preclinical, toxicological studies. These improvements may be useful to assemble other urea targets as potential therapeutic agents to combat cancer.
7
The discovery of potent cRaf1 kinase inhibitors
Karen Lackey, Michael Cory, Ronda G. Davis et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 205 citations · Full text
Patrice Mayer, P. Brunel, Céline Chaplain et al. · Journal of Medicinal Chemistry · 2000 · 20 citations · Full text